Results 221 to 230 of about 162,477 (300)

Tissue Plasminogen Activator (tPA) Use in Persistent Loculated Ascites. [PDF]

open access: yesCureus
Ali KM   +5 more
europepmc   +1 more source

Tissue Plasminogen Activator Use in Cardiac Arrest Secondary to Fulminant Pulmonary Embolism

open access: diamond, 2016
Tariq Yousuf   +8 more
openalex   +2 more sources

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 16-26, January 2026.
Abstract Chronic kidney disease (CKD) is a serious complication occurring in nearly one of three people with type 1 diabetes (T1D). Major therapeutic advances have been made in the management of CKD for people with type 2 diabetes (T2D), thereby improving their kidney, cardiovascular, and survival outcomes.
Katherine R. Tuttle   +3 more
wiley   +1 more source

Spatial Myeloid Landscape of Large Artery Atherosclerotic and Cardioembolic Thrombi Retrieved by Mechanical Thrombectomy

open access: yesThe FASEB Journal, Volume 39, Issue 23, 15 December 2025.
This study employed GeoMx digital spatial profiling of thrombi retrieved by mechanical thrombectomy from ischemic stroke patients. Spatial transcriptomic analysis revealed distinct immune signatures, suggesting subtype‐specific mechanisms of immunothrombosis. Neutrophil extracellular trap–related pathways were enriched in cardioembolic thrombi, whereas
Sugyeong Jo   +8 more
wiley   +1 more source

Understanding Cardiovascular Events With JAK Inhibitors: Similarities and Differences of the Vascular Effects Between Different JAK Inhibitors on Endothelial Cells Exposed to Inflammatory Cytokines

open access: yesACR Open Rheumatology, Volume 7, Issue 12, December 2025.
Objective A cardiovascular safety issue has been associated with JAK inhibitors (JAKi). This study compares the effects of distinct approved JAKi on endothelial cell (EC) dysfunction and apoptosis during inflammation. Methods Massive inflammation was induced in human vascular ECs by tumor necrosis factor (TNF) with interleukin‐17A (IL‐17A) treated or ...
Aliki Zavoriti, Pierre Miossec
wiley   +1 more source

Home - About - Disclaimer - Privacy